AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
AVITA Medical (NASDAQ: RCEL), a regenerative medicine company specializing in wound care management and skin restoration devices, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Jim Corbett will deliver a presentation on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time. The presentation will be available via live audio webcast on the company's investor relations website, with a replay option available after the event concludes.
AVITA Medical (NASDAQ: RCEL), un'azienda di medicina rigenerativa specializzata nella gestione delle ferite e nei dispositivi per il ripristino della pelle, ha annunciato la sua partecipazione al 43° Annuale J.P. Morgan Healthcare Conference. Il CEO Jim Corbett terrà una presentazione giovedì 16 gennaio 2025, alle 9:00 ora del Pacifico. La presentazione sarà disponibile tramite webcast audio dal vivo sul sito delle relazioni con gli investitori dell'azienda, con un'opzione di riproduzione disponibile dopo la conclusione dell'evento.
AVITA Medical (NASDAQ: RCEL), una empresa de medicina regenerativa especializada en el manejo de heridas y dispositivos para la restauración de la piel, ha anunciado su participación en la 43ª Conferencia Anual de Salud de J.P. Morgan. El CEO Jim Corbett presentará el jueves 16 de enero de 2025, a las 9:00 a.m. hora del Pacífico. La presentación estará disponible a través de una transmisión en vivo de audio en el sitio web de relaciones con inversores de la empresa, con una opción de repetición disponible después de que finalice el evento.
AVITA Medical (NASDAQ: RCEL)는 상처 관리 및 피부 복원 장비를 전문으로 하는 재생 의학 회사로서 제43회 연례 J.P. Morgan 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO 짐 코르벳은 2025년 1월 16일 목요일 오전 9시(태평양 표준시)에 발표를 진행할 예정입니다. 이 발표는 회사의 투자자 관계 웹사이트를 통해 라이브 오디오 웹캐스트로 제공되며, 행사 종료 후에는 다시 보기 옵션이 제공됩니다.
AVITA Medical (NASDAQ: RCEL), une entreprise de médecine régénératrice spécialisée dans la gestion des plaies et les dispositifs de restauration de la peau, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan sur la Santé. Le PDG Jim Corbett présentera le jeudi 16 janvier 2025, à 9h00, heure du Pacifique. La présentation sera disponible via un webinaire audio en direct sur le site des relations avec les investisseurs de l'entreprise, avec une option de rediffusion disponible après la fin de l'événement.
AVITA Medical (NASDAQ: RCEL), ein Unternehmen für regenerative Medizin, das auf das Wundmanagement und Hautrestaurationsgeräte spezialisiert ist, hat seine Teilnahme an der 43. J.P. Morgan Healthcare Conference bekannt gegeben. CEO Jim Corbett wird am Donnerstag, den 16. Januar 2025, um 9:00 Uhr Pazifischer Zeit eine Präsentation halten. Die Präsentation wird über einen Live-Audio-Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit einer Wiederholungsoption nach Abschluss der Veranstaltung.
- None.
- None.
VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time.
A live audio webcast of the presentation will be accessible under the Events & Presentations section of the Company's website at https://ir.avitamedical.com. A replay of the webcast will be available following the conclusion of the event.
About AVITA Medical, Inc.
AVITA Medical® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System, excluding RECELL GO™, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
When is AVITA Medical (RCEL) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch AVITA Medical's (RCEL) J.P. Morgan Healthcare Conference presentation?
What is AVITA Medical's (RCEL) business focus?
Who will represent AVITA Medical (RCEL) at the 2025 J.P. Morgan Healthcare Conference?
